Pencil Banner October 16 2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab in combination with rivoceranib for hepatocellular carcinoma LEARN MORE HERE
Title Image

LSKB Attending Bio International Convention in San Francisco

LSKB Attending Bio International Convention in San Francisco

LSKB is attending Bio International Convention June 6-9th in San Francisco at the Moscone Center – We are discussing product license and co-development opportunities. Schedule a meeting with us through the bio partnering system, or send us a message at alexkim@lskbiopharma.com.

PREV

LSKB Attending ASCO 2016 annual meeting

NEXT

Apatinib End-of-Phase 2 meeting scheduled with US FDA